Aim: Determine the effect of genetic variants of donors and recipients on early renal function
and tacrolimus pharmacokinetics in kidney transplant recipients. Patients & methods: We …

Purpose Multidrug resistance protein 2 (MRP2), encoded by ABCC2, has a putative role in
tacrolimus (TAC) disposition. Conflicting data exist regarding the association between …

Background The purpose of this study is to explore the association of CYP3A5, ABCB1, and
CYP2C8 polymorphisms with the risk of developing early kidney impairment in Chinese liver …

Purpose The purpose of this study was to characterize the effects of clinical and genetic
variables on the pharmacokinetics and complications of tacrolimus during the first year after …

This study investigated the effect of recipient and donor genetic variability on dose‐adjusted
steady‐state tacrolimus concentrations (Css) and clinical outcomes 3 and 6 months after …

Abstract Background: A CYP3A5 gene polymorphism is the main determinant of Tacrolimus
(Tac) dose requirements among renal transplanted patients. In spite of the utility of CYP3A5 …

Pharmacogenetics explains part of the interindividual variability in drug responses. Many
published works about the effects of single nucleotide polymorphisms (SNPs) on …

Purpose Tacrolimus is the substrate of multidrug-resistance 1 (ABCB1). However, the effect
of ABCB1 C3435T polymorphism on pharmacokinetic variables of tacrolimus is controversial …

The introduction of tacrolimus in clinical practice has improved patient survival after organ
transplant. However, despite the long use of tacrolimus in clinical practice, the best way to …

Results: The tacrolimus concentration was significantly higher in the wild (AA) group as
compared to homozygous variant (GG) and heterozygous (AG) patients. Homozygous …